“The cost is another important factor. A 2D mammography machine costs around ₹80 lakh while a 3D machine costs above ₹2 crore. Our machine, which comprises several thermal sensors and the software, costs only ₹8 lakh,” she says.
“Our equipment is easily portable. We have already done several outreach camps in partnership with clinics, companies, and non-governmental organisations,” she says.
The income mannequin is straightforward: hospitals and clinics will levy a screening cost from every affected person. For bulk customers like hospitals and large clinics, Niramai has a special pricing technique relying on their quantity. In normal, hospitals cost sufferers ₹1,500 per screening.
Niramai not too long ago obtained the CE Mark Approval, ISO 13485 and MDSAP (Medical Device Single Audit Programme) International Certifications. The CE mark approval signifies that the product could also be offered freely in any a part of the European Economic Area.
Manish Singhal, founding associate of pi Ventures and lead investor of Niramai argues that the know-how is a game-changer on how lives may be saved from breast most cancers. “With the ISO and CE certification, now Thermalytix can be made available to women beyond India especially in entire Europe, Middle East and several countries in Southeast Asia leading to global impact,” he stated in a press release.
Another board member and investor from the Japanese VC Firm, Dream Incubator, Munehiko Eto, stated, “There is a strong global need for Niramai’s breakthrough solution for breast cancer.”
Niramai has additionally developed an analogous device to display screen Covid-19 sufferers. It has put in it at two railway stations in Bengaluru.
What is subsequent on Niramai’s thoughts? “At present, research is on for similar A.I.-enabled tools to detect all kinds of cancers as well as river blindness.” So far, Niramai has raised $7 million in funding. But Manjunath is aware of it nonetheless has an extended street forward.